An open trial of citalopram in adolescents with post-traumatic stress disorder
dc.contributor.author | Seedat S. | |
dc.contributor.author | Lockhat R. | |
dc.contributor.author | Kaminer D. | |
dc.contributor.author | Zungu-Dirwayi N. | |
dc.contributor.author | Stein D.J. | |
dc.date.accessioned | 2011-05-15T15:59:18Z | |
dc.date.available | 2011-05-15T15:59:18Z | |
dc.date.issued | 2001 | |
dc.description.abstract | In this preliminary, 12-week open-label study, eight adolescents with moderate to severe post-traumatic stress disorder (PTSD) were treated with citalopram the most selective of the selective serotonin reuptake inhibitors) in a fixed daily dose of 20 mg, and rated at 2-week intervals. The Clinician-Administered PTSD Scale (Child and Adolescent Version) was the primary measure used to assess treatment outcome. Core PTSD symptoms (re-experiencing, avoidance, and hyperarousal symptoms) showed statistically significant improvement at week 12 on the Clinician-Administered PTSD Scale (Child and Adolescent Version) (CAPS-CA), with a 38% reduction in total CAPS scores between baseline and endpoint. Citalopram failed to effect improvement on self-reported depressive symptoms. All seven adolescent completers were rated as much improved or very much improved on Clinical Global impression improvement scores. Citalopram was well-tolerated overall with reported adverse experiences being relatively benign. However, larger, controlled trials are needed to consolidate these preliminary, results. © 2001 Lippincott Williams & Wilkins. | |
dc.description.version | Article | |
dc.identifier.citation | International Clinical Psychopharmacology | |
dc.identifier.citation | 16 | |
dc.identifier.citation | 1 | |
dc.identifier.issn | 2681315 | |
dc.identifier.uri | http://hdl.handle.net/10019.1/11105 | |
dc.subject | citalopram | |
dc.subject | serotonin uptake inhibitor | |
dc.subject | adolescent | |
dc.subject | article | |
dc.subject | avoidance behavior | |
dc.subject | child | |
dc.subject | clinical article | |
dc.subject | clinical trial | |
dc.subject | depression | |
dc.subject | dose response | |
dc.subject | drug tolerability | |
dc.subject | epistaxis | |
dc.subject | human | |
dc.subject | posttraumatic stress disorder | |
dc.subject | priority journal | |
dc.subject | scoring system | |
dc.subject | self report | |
dc.subject | treatment outcome | |
dc.subject | Adolescent | |
dc.subject | Arousal | |
dc.subject | Citalopram | |
dc.subject | Combined Modality Therapy | |
dc.subject | Female | |
dc.subject | Humans | |
dc.subject | Male | |
dc.subject | Personality Assessment | |
dc.subject | Psychotherapy | |
dc.subject | Stress Disorders, Post-Traumatic | |
dc.subject | Treatment Outcome | |
dc.title | An open trial of citalopram in adolescents with post-traumatic stress disorder | |
dc.type | Article |